{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:47:45Z","timestamp":1784836065446,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1151153"],"award-info":[{"award-number":["OPP1151153"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Low- and middle-income countries face a high burden of typhoid and paratyphoid fever due to poor water quality and inadequate sanitation. The World Health Organization (WHO) recommends the use of typhoid conjugate vaccines (TCV) in endemic settings and Gavi, the Vaccine Alliance, supports TCV introduction. There are currently 2 WHO-prequalified TCVs with Typbar TCV introduced in Pakistan, Liberia, and Zimbabwe. Countries should assess disease burden and consider introduction of TCV for programmatic use. Several paratyphoid vaccine candidates are in early stages of development. An effective bivalent vaccine would be the most efficient way to control typhoid and paratyphoid fever.<\/jats:p>","DOI":"10.1093\/infdis\/jiab393","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:08:59Z","timestamp":1628593739000},"page":"S770-S774","source":"Crossref","is-referenced-by-count":32,"title":["Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries"],"prefix":"10.1093","volume":"224","author":[{"given":"Mila","family":"Shakya","sequence":"first","affiliation":[{"name":"Oxford University Clinical Research Unit\u2014Nepal, Patan Academy of Health Sciences, Lalitpur, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Neuzil","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Pollard","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"2021122015212487500_CIT0001","author":"Institute for Health Metrics and Evaluation."},{"key":"2021122015212487500_CIT0002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"GBD 2017 Typhoid and Paratyphoid Collaborators","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021122015212487500_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1443-1","article-title":"Drug-resistant enteric fever worldwide, 1990 to 2018: A systematic review and meta-analysis","volume":"18","author":"Browne","year":"2020","journal-title":"BMC Med"},{"key":"2021122015212487500_CIT0004","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018\u2014recommendations","volume":"37","author":"World Health Organization","year":"2019","journal-title":"Vaccine"},{"key":"2021122015212487500_CIT0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/infdis\/145.3.292","article-title":"A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results","volume":"145","author":"Wahdan","year":"1982","journal-title":"J Infect Dis"},{"key":"2021122015212487500_CIT0006","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122015212487500_CIT0007","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1473-3099(18)30087-2","article-title":"Typhoid conjugate vaccine gets WHO prequalification","volume":"18","author":"Burki","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021122015212487500_CIT0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021122015212487500_CIT0009","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2021122015212487500_CIT0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/cid\/ciy1106","article-title":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infections among Nepalese children: a protocol for a phase III, randomized control trial","volume":"68","author":"Theiss-Nyland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015212487500_CIT0011","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1093\/cid\/ciy1103","article-title":"Typhoid vaccine acceleration consortium Malawi: a phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi","volume":"68","author":"Meiring","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015212487500_CIT0012","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/cid\/ciy1107","article-title":"Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among Bangladeshi children: a protocol for a phase IIIb trial","volume":"68","author":"Theiss-Nyland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015212487500_CIT0013","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1905047","article-title":"Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal","volume":"381","author":"Shakya","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122015212487500_CIT0014","author":"World Health Organization"},{"key":"2021122015212487500_CIT0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3855\/jidc.2495","article-title":"Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi","volume":"6","author":"Rondini","year":"2012","journal-title":"J Infect Dev Ctries"},{"key":"2021122015212487500_CIT0016","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.vaccine.2011.11.108","article-title":"Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi","volume":"30","author":"Micoli","year":"2012","journal-title":"Vaccine"},{"key":"2021122015212487500_CIT0017","volume-title":"Background paper to SAGE on typhoid vaccine policy recommendations","author":"SAGE Working Group on Typhoid Vaccines and the WHO Secretariat","year":"2017"},{"key":"2021122015212487500_CIT0018","first-page":"71:S141\u2013S150.","author":"Syed"},{"key":"2021122015212487500_CIT0019","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/cid\/ciy884","article-title":"Overview of the typhoid conjugate vaccine pipeline: current status and future plans","volume":"68","author":"Sahastrabuddhe","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021122015212487500_CIT0020","doi-asserted-by":"crossref","first-page":"100540","DOI":"10.1016\/j.eclinm.2020.100540","article-title":"Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: phase II, randomized, dose-scheduling, observer-blind study","volume":"27","author":"Capeding","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2021122015212487500_CIT0021","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijid.2020.01.045","article-title":"One-month follow up of a randomized clinical trial-phase II study in 6 to &lt;24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT typhoid conjugate vaccine","volume":"93","author":"Medise","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2021122015212487500_CIT0022","author":"International Vaccine Institute"},{"key":"2021122015212487500_CIT0023","first-page":"CD008892","article-title":"Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever","volume":"5","author":"Wijedoru","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122015212487500_CIT0024","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1473-3099(18)30804-1","article-title":"Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study","volume":"19","author":"Bilcke","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021122015212487500_CIT0025","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1128\/iai.64.7.2709-2715.1996","article-title":"Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls","volume":"64","author":"Konadu","year":"1996","journal-title":"Infect Immun"},{"key":"2021122015212487500_CIT0026","doi-asserted-by":"crossref","first-page":"e47039","DOI":"10.1371\/journal.pone.0047039","article-title":"O:2-CRM(197) conjugates against Salmonella Paratyphi A","volume":"7","author":"Micoli","year":"2012","journal-title":"PLoS One"},{"key":"2021122015212487500_CIT0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clim.2019.03.003","article-title":"Cell mediated immune responses elicited in volunteers following immunization with candidate live oral Salmonella enterica serovar Paratyphi A attenuated vaccine strain CVD 1902","volume":"201","author":"Wahid","year":"2019","journal-title":"Clin Immunol"},{"key":"2021122015212487500_CIT0028","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/cid\/cix042","article-title":"Evaluation of the clinical and microbiological response to Salmonella Paratyphi A infection in the first paratyphoid human challenge model","volume":"64","author":"Dobinson","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab393\/39661010\/jiab393.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_7\/S770\/41826180\/jiab393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_7\/S770\/41826180\/jiab393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T15:23:01Z","timestamp":1640013781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/Supplement_7\/S770\/6347515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":28,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2021,8,10]]},"published-print":{"date-parts":[[2021,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab393","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,15]]},"published":{"date-parts":[[2021,8,10]]}}}